# Apatinib as First -Line Treatment for Advanced Esophagus Cancer

> **NCT03542422** · PHASE2 · UNKNOWN · sponsor: **Affiliated Hospital of North Sichuan Medical College** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Esophagus Cancer

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03542422
- **Lead sponsor:** Affiliated Hospital of North Sichuan Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-30
- **Primary completion:** 2018-12
- **Final completion:** 2019-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542422, "Apatinib as First -Line Treatment for Advanced Esophagus Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03542422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*